Neuronetics announced a strategic collaboration with ANT Neuro to integrate image-guided neuronavigation into NeuroStar Advanced Therapy. Under the preferred partnership, Neuronetics will offer ANT Neuro's visor2 neuronavigation system alongside NeuroStar, enabling real-time spatial tracking and 3D visualization during TMS treatment.
The companies describe the pairing of a market-leading TMS platform with dedicated neuronavigation technology as a first of its kind. It lets providers incorporate precise, individualized coil targeting into their NeuroStar workflows — a capability increasingly associated with accelerated and personalized TMS protocols.
The two companies planned to showcase the partnership at the American Psychiatric Association Annual Meeting in May and the Clinical TMS Society Annual Meeting in June, with a broader commercial rollout in the second half of 2026.
For clinics, the addition addresses growing clinical interest in imaging-guided targeting as an alternative to scalp-based landmarks such as Beam F3. Neuronetics trades on Nasdaq under STIM and owns the Greenbrook TMS clinic network.
Source
Reporting based on coverage from GlobeNewswire. This article is editorial summary intended for general information; it is not medical advice.
